FDA Issues Form 483 to Biocon in Bangalore, India
Resilinc-blog

According to Biopharma, the United States Food and Drug Administration (USFDA) issued a Form 483 to Biocon regarding its plant in Bangalore, Karnataka, India.

Read All Global Disruptions

Recent Global Disruptions